

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

---

In re Patent Application of:  
Petra Lutter et al.

Application No.: 10/564,588

Confirmation No.: 3511

Filed: February 10, 2006

Art Unit: 1647

For: REGULATORY T-CELLS CONTAINING  
GALECTINS FOR THE THERAPY AND  
DIAGNOSIS OF DISEASES

---

Examiner: Davis S. Romeo

**RESPONSE TO RESTRICTION REQUIREMENT**

MS Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

The restriction requirement set forth in the Office action dated May 26, 2009 respectfully is traversed. Applicants respectfully contend that unity of invention is established among all claims 1–26. The Examiner restricted the claims into the following groups:

Group I – claims 1-11, and 20-26 (in part), drawn to a CD4+CD25+ T-cell comprising galectin-10, and

Group II – Claims 12-19 and 20-26 (in part), drawn to a binding agent that binds a CD4+CD25+ T-cell comprising galectin-10.

The Examiner has asserted that the inventions in Groups I and II do not relate to a single inventive concept under PCT Rule 13.1 because they lack the same or corresponding special technical feature under PCT Rule 13.2, specifically, a CD4+CD25+ T-cell comprising galectin-10 as to Group I and a binding agent that binds a CD4+CD25+ T-cell comprising galectin-10 as